HIGHLIGHTS
- who: Top from the Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA have published the article: of GSK-3 in prostate cancer cells inhibit prostate cancer, in the Journal: (JOURNAL)
- what: Together the authors provide novel insight into the Src-mediated Y216 GSK-3 phosphorylation and activation in prostate cancer cells and reveal the potential benefits of targeting Src-GSK-3 axis using drugs such as dasatinib. Collectively, the study demonstrated the integral role of Src in mediating Y216 GSK-3 phosphorylation and subsequent activation leading for prostate cancer growth in_vivo . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.